X4 PHARMACEUTICALS, INC Reclassifications of Temporary to Permanent Equity
X4 PHARMACEUTICALS, INC (XFOR) reported Reclassifications of Temporary to Permanent Equity of -$101.17 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Financial Statements › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2025-03-26
- X4 PHARMACEUTICALS, INC reclassifications of temporary to permanent equity for the quarter ending 2023-09-30 was $2.00K, a 99.99% decline year-over-year.
- X4 PHARMACEUTICALS, INC reclassifications of temporary to permanent equity for the quarter ending 2022-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC reclassifications of temporary to permanent equity for the quarter ending 2022-09-30 was $38.75M.
- X4 PHARMACEUTICALS, INC reclassifications of temporary to permanent equity for fiscal 2023 was -$101.17M, a 361.05% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC reclassifications of temporary to permanent equity for fiscal 2022 was $38.75M.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 6 month | Reclassifications of Temporary to Permanent Equity 9 month | Reclassifications of Temporary to Permanent Equity 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$101.17M 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $2.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $38.75M derived: sum of 2 quarters · filed 2025-03-26 | $38.75M 10-K · filed 2025-03-26 | |
| 2022-09-30 | $38.75M 10-Q · filed 2023-11-09 | $38.75M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |